AEMD

Aethlon Medical

Stock NASDAQ – Stock Market Prices, News & Analysis

Aethlon Medical Inc est une société de biotechnologie concentrée sur le développement de dispositifs médicaux pour traiter des maladies infectieuses et cancéreuses.

$ 2.32
0.87 %

Aethlon Medical

$ 2.32
0.87 %
AEMD

Aethlon Medical Inc est une société de biotechnologie concentrée sur le développement de dispositifs médicaux pour traiter des maladies infectieuses et cancéreuses.

Price history of Aethlon Medical
Price history of Aethlon Medical

Performance & Momentum

6 Months 57.82 %
1 Year 91.71 %
3 Years 99.26 %
5 Years 99.84 %

Strategic Analysis

Aethlon Medical • 2026

Aethlon Medical Inc specializes in the development of innovative medical devices for the treatment of infectious and cancer diseases, positioning its business model at the intersection of biotechnology and medical technology. This targeted niche within the healthcare sector offers differentiated potential, although the company is still in the pre-commercial stage with significant execution risk.

Strengths
  • Focus on innovative medical devices addressing significant unmet medical needs
  • Positioning in critical diseases with the potential for meaningful clinical impact
Weaknesses
  • Very poor stock performance with a sustained downward trend over several years
  • No recent news or evidence showing tangible progress toward commercialization
Momentum

Momentum is extremely weak, reflecting a continued loss of investor confidence and a sharp decline in the share price. This situation calls for significant strategic caution for retail investors, who should view the stock as highly speculative in the absence of visible catalysts.

Similar stocks to Aethlon Medical

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone